Robert Pilarski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1386355/publications.pdf

Version: 2024-02-01

44	4,909	236612	276539
papers	citations	25 h-index	41 g-index

44	44	44	7515
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic evaluation of patients and families with concern for hereditary endocrine tumor syndromes. Familial Cancer, 2022, 21, 93-100.	0.9	0
2	Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. Cancers, 2022, 14, 2426.	1.7	3
3	How Have Multigene Panels Changed the Clinical Practice of Genetic Counseling and Testing. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 103-108.	2.3	9
4	BAP1 Tumor Predisposition Syndrome. , 2021, , 23-36.		2
5	Impact of Previous Genetic Counseling and Objective Numeracy on Accurate Interpretation of a Pharmacogenetics Test Report. Public Health Genomics, 2021, 24, 26-32.	0.6	11
6	Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. Translational Behavioral Medicine, 2020, 10, 337-346.	1.2	9
7	Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma. Ophthalmology, 2020, 127, 668-678.	2.5	27
8	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
9	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	2.3	314
10	PTEN Hamartoma Tumor Syndrome: A Clinical Overview. Cancers, 2019, 11, 844.	1.7	119
11	The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 79-86.	1.8	73
12	MIF promoter polymorphisms are associated with epiretinal membrane but not retinal detachment with PVR in an american population. Experimental Eye Research, 2019, 185, 107667.	1.2	5
13	Germline large deletion of BAP1 and decreased expression in nonâ€tumor choroid in uveal melanoma patients with high risk for inherited cancer. Genes Chromosomes and Cancer, 2019, 58, 650-656.	1.5	9
14	â€œSecondâ€Class Status?â€•Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome. Journal of Genetic Counseling, 2018, 27, 885-893.	0.9	16
15	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	3.0	164
16	Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1â€tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes and Cancer, 2018, 57, 478-481.	1.5	6
17	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	2.3	408
18	Germline BAP1 alterations in familial uveal melanoma. Genes Chromosomes and Cancer, 2017, 56, 168-174.	1.5	60

#	Article	IF	Citations
19	PTEN Promoter Variants Are Not Associated With Common Cancers: Implications for Multigene Panel Testing. JCO Precision Oncology, 2017, 1, 1-7.	1.5	2
20	Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 153-162.	2.3	153
21	Genetic markers of pigmentation are novel risk loci for uveal melanoma. Scientific Reports, 2016, 6, 31191.	1.6	28
22	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
23	Correspondence. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, l-li.	2.3	1
24	Germline BAP1 mutations misreported as somatic based on tumor-only testing. Familial Cancer, 2016, 15, 327-330.	0.9	13
25	Risk factors for anthracycline-associated cardiotoxicity. Supportive Care in Cancer, 2016, 24, 2173-2180.	1.0	39
26	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	0.8	521
27	PTEN Is a Negative Regulator of NK Cell Cytolytic Function. Journal of Immunology, 2015, 194, 1832-1840.	0.4	37
28	Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo. Genes and Development, 2015, 29, 1707-1720.	2.7	29
29	Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle, 2015, 14, 2091-2099.	1.3	11
30	Colonic manifestations ofPTENhamartoma tumor syndrome: Case series and systematic review. World Journal of Gastroenterology, 2014, 20, 1833.	1.4	51
31	Response. Journal of the National Cancer Institute, 2014, 106, dju131.	3.0	0
32	Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes and Cancer, 2014, 53, 177-182.	1.5	95
33	Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria. Journal of the National Cancer Institute, 2013, 105, 1607-1616.	3.0	483
34	Phosphatase and Tensin Homolog Immunohistochemical Staining and Clinical Criteria for Cowden Syndrome in Patients With Trichilemmoma or Associated Lesions. American Journal of Dermatopathology, 2013, 35, 637-640.	0.3	18
35	Genetic Testing by Cancer Site. Cancer Journal (Sudbury, Mass), 2012, 18, 364-371.	1.0	13
36	The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLoS ONE, 2012, 7, e37891.	1.1	30

#	Article	IF	Citations
37	Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. Journal of Medical Genetics, 2011, 48, 856-859.	1.5	432
38	Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. Journal of Medical Genetics, 2011, 48, 505-512.	1.5	139
39	Genetic/Familial High-Risk Assessment: Breast and Ovarian. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 562-594.	2.3	253
40	Cowden Syndrome: A Critical Review of the Clinical Literature. Journal of Genetic Counseling, 2009, 18, 13-27.	0.9	297
41	Risk Perception Among Women at Risk for Hereditary Breast and Ovarian Cancer. Journal of Genetic Counseling, 2009, 18, 303-312.	0.9	29
42	Molecular Classification of Patients With Unexplained Hamartomatous and Hyperplastic Polyposis. JAMA - Journal of the American Medical Association, 2005, 294, 2465.	3.8	218
43	Germline PTEN Promoter Mutations and Deletions in Cowden/Bannayan-Riley-Ruvalcaba Syndrome Result in Aberrant PTEN Protein and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway. American Journal of Human Genetics, 2003, 73, 404-411.	2.6	283
44	Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*. American Journal of Human Genetics, 2001, 69, 704-711.	2.6	236